ClinicalTrials.gg
CompletedNCT00296192Updated Oct 2, 2014Results posted

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

A Phase 2 interventional study of Rotigotine nasal spray and Placebo in Parkinson's Disease, sponsored by UCB Pharma. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
26th of 42
82 · median 123
Started
2006
with 4 others
Phase 2
7 of 44
none open now
Registered
6th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 26th largest by enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2006, is one of 7 in phase 2, and was the 6th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952) in a single dose application scheme.

Subjects will undergo a 2 - 28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, subjects will be randomly assigned either to rotigotine or placebo nasal spray and will then receive a single dose of trial medication. Safety assessments after application include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks. Efficacy will be assessed by application of motor examination scores.

The first subject is planned to be enrolled in February 2006. The last subject is planned to be enrolled in May 2006. Last subject out is expected for August 2006.

Read the detailed description

The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952)in a single dose application scheme. Subjects will undergo a 2-28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, subjects will be randomly assigned either to rotigotine or placebo nasal spray and will then receive a single dose of trial medication. Safety assessments after application include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks. Efficacy will be assessed by application of motor examination scores.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Rotigotine nasal spray
  • Efficacy, safety and tolerability
  • Parkinson's disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with idiopathic Parkinson's disease for at least 3 years in duration
  • At least 30 years of age

Exclusion criteria

Exclusion Criteria:

  • Patients with atypical Parkinson's or concomitant diseases or medical conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Placebo comparator
    Placebo 1

    Placebo nasal spray 1 - 4 puffs

    Other: Placebo

  • Experimental
    Rotigotine 1

    Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)

    Drug: Rotigotine nasal spray

  • Experimental
    Rotigotine 2

    Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)

    Drug: Rotigotine nasal spray

  • Experimental
    Rotigotine 3

    Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)

    Drug: Rotigotine nasal spray

  • Experimental
    Rotigotine 4

    Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)

    Drug: Rotigotine nasal spray

Interventions

  • Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries

    Also known as: Neupro, SPM 952

  • OtherPlacebo

    placebo nasal spray 1, 2 3, and 4 puffs

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Complete the Trial

    Time frame: 15 days

Secondary outcomes

  1. Change From Baseline at 24 Minutes Post-dose in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination

    The Unified Parkinson's Disease Rating Scale (UPDRS) is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Examination. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 24 minute value minus baseline value.

    Time frame: Baseline, and 24 minutes post-dose

  2. Change From Baseline to 34 Minutes Post-dose in Tapping Rate (Taps/Min)

    One-minute tapping rate will be calculated as the number of times a subject could tap on two 4 x 4 cm marks placed on a board 30 cm apart during 1 minute (30 cm measured from the inner border of the two boxes).

    Time frame: Baseline and 34 minutes post-dose

  3. "Success Rate" (Percentage of Subjects Achieving "Off" Reversals)

    Subjects reversing from "off" to "on" following initiation of treatment. "On" and "off" state refer to periods where Parkinson's disease symptoms are not present ("on") and periods where symptoms are present ("off"); the "on"/"off" determination at each assessment timepoint was made by the investigator.

    Time frame: Up to 6 hours post-dose

  4. Time of First "Off" Reversal

    Number of minutes to first reversal of symptoms from "off" to "on". Estimated via Kaplan-Meier estimation method. "On" and "off" state refer to periods where Parkinson's disease symptoms are not present ("on") and periods where symptoms are present ("off"); the "on"/"off" determination at each assessment timepoint was made by the investigator.

    Time frame: Up to 6 hours post-dose

07

Results

Posted Jan 29, 2010

Participant flow

Participant flow — Overall Study
MilestonePlacebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 Puffs
Started1716161716
Completed1716161716
Not completed00000

Outcome measures

PrimaryNumber of Subjects Who Complete the Trial
Time frame:
15 days
Reported as:
Number · participants
Number of Subjects Who Complete the Trial
participantsPlacebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 Puffs
Number of Subjects Who Complete the Trial1716161716
SecondaryChange From Baseline at 24 Minutes Post-dose in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination

The Unified Parkinson's Disease Rating Scale (UPDRS) is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Examination. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 24 minute value minus baseline value.

Time frame:
Baseline, and 24 minutes post-dose
Reported as:
Mean · score on a scale
Change From Baseline at 24 Minutes Post-dose in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination
score on a scalePlacebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 Puffs
Baseline35.1 ± 7.7737.2 ± 10.6839.5 ± 12.9436.2 ± 7.6037.6 ± 9.30
24 minutes post-dose25.3 ± 12.4430.0 ± 11.3529.2 ± 13.5329.1 ± 8.5126.4 ± 12.95
Change from baseline to 24 minutes post-dose-9.8 ± 7.8-7.2 ± 10.32-10.3 ± 6.17-7.1 ± 6.47-11.6 ± 10.65
Statistical analysis
  • Placebo 1-4 Puffs vs Rotigotine 1 Puff · ANCOVA · Mean difference (net): 2.9 · 95% CI -2.9 to 8.7
  • Placebo 1-4 Puffs vs Rotigotine 2 Puffs · ANCOVA · Mean difference (net): 0.1 · 95% CI -5.7 to 6.0
  • Placebo 1-4 Puffs vs Rotigotine 3 Puffs · ANCOVA · Mean difference (net): 2.9 · 95% CI -2.8 to 8.6
  • Placebo 1-4 Puffs vs Rotigotine 4 Puffs · ANCOVA · Mean difference (net): -1.4 · 95% CI -7.4 to 4.6
SecondaryChange From Baseline to 34 Minutes Post-dose in Tapping Rate (Taps/Min)

One-minute tapping rate will be calculated as the number of times a subject could tap on two 4 x 4 cm marks placed on a board 30 cm apart during 1 minute (30 cm measured from the inner border of the two boxes).

Time frame:
Baseline and 34 minutes post-dose
Reported as:
Mean · taps per minute
Change From Baseline to 34 Minutes Post-dose in Tapping Rate (Taps/Min)
taps per minutePlacebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 Puffs
Baseline112.7 ± 47.08109.8 ± 28.94127.2 ± 44.33115.9 ± 41.05118.3 ± 40.41
34 minutes post-dose141.2 ± 50.92131.0 ± 30.01138.7 ± 44.42142.9 ± 51.20144.4 ± 57.64
Change from baseline to 34 minutes post-dose28.5 ± 27.8321.2 ± 26.6911.5 ± 11.2727.1 ± 25.2522.9 ± 27.75
Statistical analysis
  • Placebo 1-4 Puffs vs Rotigotine 1 Puff · ANCOVA · Mean difference (net): -8.6 · 95% CI -25.7 to 8.5
  • Placebo 1-4 Puffs vs Rotigotine 2 Puffs · ANCOVA · Mean difference (net): -16.8 · 95% CI -34.0 to 0.4
  • Placebo 1-4 Puffs vs Rotigotine 3 Puffs · ANCOVA · Mean difference (net): -1.4 · 95% CI -18.2 to 15.4
  • Placebo 1-4 Puffs vs Rotigotine 4 Puffs · ANCOVA · Mean difference (net): -5.5 · 95% CI -23.3 to 12.2
Secondary"Success Rate" (Percentage of Subjects Achieving "Off" Reversals)

Subjects reversing from "off" to "on" following initiation of treatment. "On" and "off" state refer to periods where Parkinson's disease symptoms are not present ("on") and periods where symptoms are present ("off"); the "on"/"off" determination at each assessment timepoint was made by the investigator.

Time frame:
Up to 6 hours post-dose
Reported as:
Number · percentage of participants
"Success Rate" (Percentage of Subjects Achieving "Off" Reversals)
percentage of participantsPlacebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 Puffs
Reversed from "off" to "on" (success)70.650.075.070.675.0
Did not reverse from "off" to "on"29.450.025.029.425.0
Statistical analysis
  • Placebo 1-4 Puffs vs Rotigotine 1 Puff · Confidence interval · Difference in proportions: -20.6 · 95% CI -53.3 to 12.1
  • Placebo 1-4 Puffs vs Rotigotine 2 Puffs · 95% confidence interval · Difference in proportions: 4.4 · 95% CI -25.9 to 34.7
  • Placebo 1-4 Puffs vs Rotigotine 3 Puffs · 95% confidence interval · Difference in proportions: 0.0 · 95% CI -30.6 to 30.6
  • Placebo 1-4 Puffs vs Rotigotine 4 Puffs · 95% confidence interval · Difference in proportions: 4.4 · 95% CI -25.9 to 34.7
SecondaryTime of First "Off" Reversal

Number of minutes to first reversal of symptoms from "off" to "on". Estimated via Kaplan-Meier estimation method. "On" and "off" state refer to periods where Parkinson's disease symptoms are not present ("on") and periods where symptoms are present ("off"); the "on"/"off" determination at each assessment timepoint was made by the investigator.

Time frame:
Up to 6 hours post-dose
Reported as:
Median · minutes
Time of First "Off" Reversal
minutesPlacebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 Puffs
Time of First "Off" Reversal50 (24 to 65)60 (40 to 60)51 (22 to 84)50 (35 to 70)59 (35 to 190)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo 1-4 Puffs—0/13 (0%)3/13 (23.1%)
Rotigotine 1 Puff—0/17 (0%)9/17 (52.9%)
Rotigotine 2 Puffs—1/17 (5.9%)5/17 (29.4%)
Rotigotine 3 Puffs—0/18 (0%)9/18 (50%)
Rotigotine 4 Puffs—1/17 (5.9%)9/17 (52.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 Puffs
BradycardiaCardiac disorders0/130/170/170/181/17
DepressionPsychiatric disorders0/130/171/170/180/17
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlacebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 Puffs
NauseaGastrointestinal disorders2/130/170/170/183/17
Application site reactionGeneral disorders0/131/173/170/182/17
DizzinessNervous system disorders1/131/171/171/183/17
SomnolenceNervous system disorders1/132/172/173/181/17
VomitingGastrointestinal disorders0/130/170/170/182/17
Nasal congestionRespiratory, thoracic and mediastinal disorders0/130/170/170/182/17
HyperhidrosisSkin and subcutaneous tissue disorders0/130/170/170/182/17
Application site irritationGeneral disorders0/131/170/172/180/17
Atrioventricular block first degreeCardiac disorders1/130/170/170/180/17
Urinary tract infectionInfections and infestations1/131/171/171/181/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 PuffsTotal
<=18 years000000
Between 18 and 65 years98591041
>=65 years88118641
Age, Continuous
Age, Continuous(years)Placebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 PuffsTotal
Mean63.9 ± 6.9467.1 ± 7.5466.8 ± 9.6763.9 ± 8.2860.5 ± 8.0464.4 ± 8.28
Sex: Female, Male
Sex: Female, Male(Participants)Placebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 PuffsTotal
Female4547424
Male131112101258
Region of Enrollment
Region of Enrollment(participants)Placebo 1-4 PuffsRotigotine 1 PuffRotigotine 2 PuffsRotigotine 3 PuffsRotigotine 4 PuffsTotal
Germany111212101358
Austria2214110
United Kingdom112026
Spain311308
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2006
First posted
Feb 24, 2006
Start
Feb 2006
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Results first posted
Jan 29, 2010
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00296192
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Feb 24, 2006
Start date
Feb 2006
Primary completion
Jun 2006
Completion
Jun 2006
Results posted
Jan 29, 2010
Last update
Oct 2, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion